Latest News — Page 3

Mounjaro passed €1 million in pharmacy sales in a single day in Portugal, on more than 3,000 packs, and the Ordem dos Médicos has asked Infarmed for prescription data. Here is what the numbers show on access, reimbursement and supply. #SyenzaNews #GLP1 #MarketAccess

New OHE research puts the economic burden of obesity in eight European countries at 0.7% to 1.4% of GDP. Germany carries the largest bill at EUR 55.2bn; the UK carries the largest productivity share at 58%. #SyenzaAI #SyenzaNews #MarketAccess #HealthEconomics #Obesity

Syenza’s webinar on AI governance in HTA drew 71% of participants who had not yet used AI in their work. The session covered the paper’s governance checklist, the in-house Navigator tool, and a live rapid HTA of rituximab in lupus. #SyenzaNews #HTA #AIinHealth #MarketAccess

Minimal stimulation IVF lowers the cost of a cycle. A health economist and a US patient advocate told an IFFS webinar that the savings case, and the bill patients carry, are both unsettled. #SyenzaNews #IVF #MarketAccess #HealthEconomics

Sweden’s pharmaceutical injury insurance logged 33 semaglutide adverse reactions claims in the first eight months of 2026, up from 13 in all of 2025. More prescribing and more awareness explain the rise better than any new risk.

#SyenzaNews #pharmaceuticals #drugsafety #regulatoryaffairs

South Africa has set a second single exit price adjustment for 2026, lifting listed medicine prices by 2.88% from 1 October. #SyenzaNews #MarketAccess #Pharma

Roche’s dual GLP-1/GIP agonist enicepatide met both Phase II endpoints in type 2 diabetes, cutting HbA1c 2.65% and weight 15.5% at 48 weeks. #SyenzaNews #type2diabetes #GLP1 #obesity

COMP’s July 2026 sitting recommended 12 orphan drug designations, withdrew four, and sharpened the test for significant benefit against authorised therapies. #SyenzaNews #OrphanDrugs #MarketAccess #RareDiseases

Nine pharma chairs, from AstraZeneca to Sanofi, warn Europe is losing the pharmaceutical investment race to the US and China, and call on governments to treat medicines as strategic infrastructure. #SyenzaNews #pharmaceuticals #MarketAccess #drugdevelopment

SAHPRA reports a clean audit, WHO ML3 vaccine maturity, and ICH membership in its 2025/26 annual report, with R515.7 million in revenue and a R33.7 million surplus. #SyenzaNews #MarketAccess #SAHPRA

Regional networks anchored to local contexts are the missing link for responsible AI in low-resource health systems, a new npj Digital Medicine Perspective argues. #ResponsibleAI #DigitalHealth #GlobalHealth #HealthEquity

The FDA has granted full approval to Inluriyo plus Verzenio for ESR1-mutated metastatic breast cancer. In the Phase 3 EMBER-3 trial, the all-oral combination doubled median progression-free survival versus Inluriyo alone, at 11.1 months versus 5.5 months. #SyenzaNews #Oncology #MarketAccess

HTAsiaLink 2026 brought HTA agencies, researchers and patient representatives together in Taipei to weigh real-world evidence, AI and patient involvement against the realities of different Asia-Pacific health systems. #HTA #HealthEconomics #MarketAccess

Nigeria’s NHIA has inaugurated a national health technology assessment steering committee to anchor healthcare spending in evidence. #SyenzaNews #HTA #HealthEconomics #Nigeria

The European Commission has published three templates that formalise written input from patients, carers and clinicians in EU Joint Clinical Assessments, locking it onto the scope proposal and the draft report. #HTA #JCA #MarketAccess

Portugal pharmaceutical exports climbed 42.9% in 2025 to €5.0 billion. Without that increase, national goods exports would have contracted. #SyenzaNews #MarketAccess #Pharma